Dong Wei – CEO, EdiGene, China
Dr Dong Wei, CEO of EdiGene, shares the fascinating story behind the establishment of EdiGene, including his close relationship with EdiGene founder Professor Wensheng Wei; the insights he bring from…
Jiangsu Hengrui Medicine Co., Ltd. engages in the manufacture and distribution of pharmaceutical and health food products. Its business activities include the development, manufacture, and distribution of raw chemical pharmaceuticals, injections, tablets, capsules, western medicines, medicine packaged materials, and raw medicines. It also engages in the manufacture and sale of SP aluminium foil, PTP aluminium foil, OP protection preparation and VC adhesive. The company was founded in 1970 and is headquartered in Lianyungang, China.
Dr Dong Wei, CEO of EdiGene, shares the fascinating story behind the establishment of EdiGene, including his close relationship with EdiGene founder Professor Wensheng Wei; the insights he bring from…
Speaking in May 2019, Dr Dajun Yang, chairman, executive director and CEO of Ascentage Pharma, shares the company’s top highlights over the past decade; their strong product pipeline and portfolio…
Mark Lotter, founder and CEO of Nuance Biotech, explains why he decided to return to the China market to establish Nuance Biotech, two years after his retirement. He also shares…
Michael Zhang, chairman of Peijia Medical, shares Peijia Medical’s mission to become a two-platform medical device company as well as the partner of choice for physicians in China and globally.…
PharmaBoardroom recently analysed the contents of 10 interviews conducted with country managers at multinational pharma companies in China. We found some underlying themes present in the majority of the interviews,…
Dr. Zhang Yu, CEO of Aeon Therapeutics, shares the unique journey that motivated him to establish Aeon Therapeutics, as a joint venture of Chinese VcanBio and US-based Eureka Therapeutics, to…
With proactive government support and an increasingly specialised workforce, China has become one of the leading nations in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, along with the…
Juergen Kurz takes us through HEUFT’s unique technology that is revolutionizing the quality of packaging in the pharmaceutical industry in a country, China, where quality compliance is now an issue. …
China’s new Amended Drug Administration Law is being enacted to strengthen and streamline its regulation of the pharmaceutical industry. The amended law seeks to address prominent problems in the pharmaceutical…
China’s new Amended Drug Administration Law is being enacted to strengthen and streamline its regulation of the pharmaceutical industry as well as address prominent problems such as counterfeit drugs, substandard…
Tao Chen, head of business development of Absea and CEO of the new spin-out Agsea, is entering the world of immunodiagnostics with a comprehensive panel of IHC antibodies in the…
China’s booming pharmaceutical industry has been rapidly expanding to become the second largest pharmaceutical market globally. The following are the top ten Chinese pharma companies from 2018, with revenues reaching over…
See our Cookie Privacy Policy Here
